CBD diformate | 1110598-82-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: CBD diformate
• 英文别名: [3-formyloxy-2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylphenyl] formate
• CAS: 1110598-82-7
• 化学式: C₂₃H₃₀O₄
• 分子量: 370.489
• InChiKey: XZGJIMSQERWSQA-VQTJNVASSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  27
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  反式-薄荷基-2,8-二烯-1-醇 在 4-二甲氨基吡啶 、 对甲苯磺酸 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 7.08h， 生成 CBD formate 、 CBD diformate
  参考文献：
  名称：

  PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME

  摘要：

  本文描述了大麻二酚前药，制备大麻二酚前药的方法，包含大麻二酚前药的配方以及使用大麻二酚的方法。本文描述的一个实施例涉及通过经皮或局部给药大麻二酚前药来治疗和预防疾病和/或疾病。

  公开号：

  US20090036523A1

文献信息

• [EN] USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES<br/>[FR] UTILISATION DE PROMÉDICAMENTS DE CANNABIDIOL POUR ADMINISTRATION TOPIQUE ET TRANSDERMIQUE AVEC DES MICRO-AIGUILLES
  申请人：ALLTRANZ INC

  公开号：WO2011026144A1

  公开（公告）日：2011-03-03

  Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.

  本文描述了微针药物递送系统，包括含有药物活性成分（例如大麻二酚和大麻二酚前药）的药物组合物和适用于将活性成分局部或全身性递送至哺乳动物的微针阵列。本文还描述了使用微针经皮或局部药物递送系统治疗疾病，包括胰腺炎和胰腺癌的方法，其中药物组合物包括大麻二酚和大麻二酚前药，并且使用微针阵列。
• FORMULATIONS OF CANNABIDIOL AND PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME
  申请人：Stinchcomb Audra Lynn

  公开号：US20100273895A1

  公开（公告）日：2010-10-28

  Described herein are pharmaceutical compositions comprising a cannabinoid, such as cannabidiol or a cannabidiol prodrug, which is metabolized to cannabidiol, and a penetration enhancer. Also described herein are methods of using the same. One embodiment described herein relates to the transdermal or topical administration of pharmaceutical compositions comprising a cannabinoid, such as cannabidiol or a cannabidiol prodrug, and a penetration enhancer to a person in need thereof.
• USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES
  申请人：Stinchcomb Audra Lynn

  公开号：US20110052694A1

  公开（公告）日：2011-03-03

  Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.
• Cannabinoid-Containing Compositions and Methods for Their Use
  申请人：Stinchcomb Audra L.

  公开号：US20120202891A1

  公开（公告）日：2012-08-09

  This invention relates to cannabinoid-containing compositions, particularly cannabinoid-containing gel formulations and methods for the treatment of traumatic injury, e.g., strains, sprains and contusions, and disease conditions, e.g., arthritis, particularly osteoarthritis. The methods involve topically applying a cannabinoid or a cannabinoid-containing composition to a subject's skin near, or distant from, the area of the injury or the area affected by the disease condition, e.g., an arthritic joint. The cannabinoid-containing composition is preferably a pharmaceutically acceptable gel containing a therapeutically effective amount of a cannabinoid sufficient to alleviate the symptoms associate with the injury or disease condition.
• US8293786B2
  申请人：——

  公开号：US8293786B2

  公开（公告）日：2012-10-23